7月17日，Cencora盘前上涨3.25%，报318.0美元/股，成交额540.03万美元。
消息面上，近期多重利好持续催化。Evercore ISI于7月7日将公司目标价由300美元上调至330美元，维持跑赢大盘评级。此前，公司董事长Mark Durcan以每股266美元买入4000股、总额约100万美元，为其任期内金额最大的一次增持，被评为"异常大额"。同时，公司宣布恢复股票回购计划，授权规模高达20亿美元。此外，公司与吉利德旗下Kite达成CAR-T细胞疗法分销协议，进一步拓展专业药品分销业务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.